284 results on '"Krebs, Shelly J"'
Search Results
2. Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice
3. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
4. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption
5. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
6. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
7. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
8. CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people with HIV
9. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine
10. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
11. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes
12. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.
13. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection
14. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma
15. Preferential and persistent impact of acute HIV-1 infection on CD4⁺ iNKT cells in colonic mucosa
16. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
17. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
18. Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding
19. Informing the Need for a SARS-CoV-2 Booster Based Upon the Immune Responses among Young Healthy Adults to Variants Circulating in Late 2023
20. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
21. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
22. Neurologic signs and symptoms frequently manifest in acute HIV infection.
23. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals
24. Informing the need for a SARS-CoV-2 booster based upon the immune response among young, healthy adults to variants circulating during late 2023
25. Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States
26. CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people living with HIV
27. Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities
28. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor
29. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research
30. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
31. CD4 dim CD8 bright T cells are inversely associated with neuro-inflammatory markers among people with HIV.
32. Distinct mucosal and systemic immunological characteristics in transgender women potentially relating to HIV acquisition
33. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
34. Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments
35. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection
36. CD4dimCD8brightT cells are inversely associated with neuro-inflammatory markers among people with HIV
37. Monocyte and CD4+ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment
38. Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART
39. Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters
40. Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies
41. Fc receptor engagement of HIV-1 Env-specific antibodies in mothers and infants predicts reduced vertical transmission
42. Improvement of antibody responses by HIV envelope DNA and protein co-immunization
43. Susceptibility to Human Immunodeficiency Virus Type 1 Acquisition Linked to Malaria Exposure: A Case-Control Study
44. Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection
45. HIV-1 infections with multiple founders associate with the development of neutralization breadth
46. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
47. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
48. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
49. Vaccine Delivery to the Oral Cavity Using Coated Microneedles Induces Systemic and Mucosal Immunity
50. Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.